1 results match your criteria Clinical Ovarian Cancer [Journal]

  • Page 1 of 1

Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma.

Clin Ovarian Cancer Other Gynecol Malig 2011 Jun;4(1):26-33

Gynecologic Oncology Program, Brigham and Women's Hospital, Boston, MA.

OBJECTIVE: To explore the safety, efficacy, and biomarkers of bevacizumab with gemcitabine and oxaliplatin in women with recurrent platinum-sensitive ovarian carcinoma. METHODS: The patients received bevacizumab (10 mg/kg), gemcitabine (1000 mg/m(2)), and oxaliplatin (65 mg/m(2)) on days 1 and 15 in 28-day cycles. The patients with safely accessible tumor underwent intratumoral fluid pressure (IFP) measurements and positron-emission tomographies immediately and 2 weeks after treatment. Read More

View Article

Download full-text PDF

http://dx.doi.org/10.1016/j.cloc.2011.04.003DOI Listing
June 2011
36 Reads
  • Page 1 of 1